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Abstract
Background: We correlated genotypes, virulence factors and antimicrobial susceptibility patterns
of nosocomially identified Pseudomonas aeruginosa isolates from clinical specimens to those of
environmental isolates encountered in the same units of a medical center. Antibiotic susceptibility
testing, RAPD analysis and detection of enzymatic activities of extracellular virulence factors, were
done on these isolates.
Results: Data showed that most of the clinical and environmental isolates were susceptible to
tested antimicrobial agents. RAPD analysis determined the presence of 31 genotypes, with
genotype 1 detected in 42% of the clinical isolates and 43% of the environmental isolates. Enzymatic
activity testing showed that genotype 1 produced all virulence factors tested for.
Conclusion: In conclusion, our data demonstrated the predominant prevalence of a potentially
virulent P. aeruginosa genotype, circulating in a number of units of the medical center and emphasize
the need to reinforce infection control measures.
Background
Despite the advances in hospital care and the introduction
of a wide variety of antimicrobial agents, Pseudomonas aer-
uginosa continues to be a major nosocomial pathogen par-
ticularly in patients who suffer from immunosuppression
[1]. P. aeruginosa is a ubiquitous pathogen prevalent in the
hospital environments, and can cause severe nosocomial
infections [2]. The latter involve a broad spectrum of
infections including the respiratory, gastrointestinal, and
urinary tracts as well as wound infections, sepsis and oth-
ers [3]. Various possible sources of P. aeruginosa infection
in hospitals have been identified; such as tap water, med-
ical equipment, hospital personnel and other patients
[2,4].  P. aeruginosa accounts for 10% of all hospital
acquired infections, a site specific prevalence which may
vary from one unit to another and from study to study [5].
Among data on site-specific infections, P. aeruginosa
appears to be the major cause of ventilator-associated
pneumonia with a high rate of attributable mortality [6].
Moreover this organism can contaminate a number of
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other medical equipment such as respirators, endoscopes,
bronchoscopes, transvenous pacemakers, urinary cathe-
ters, and dialysis equipment, leading to site-related infec-
tions [7,8]. During the last year, the average prevalence of
P. aeruginosa nosocomial infections in our medical center
was 18%. Such a high rate prompted us to study the P. aer-
uginosa genotypes circulating in the various units to reveal
the clonal relationship between clinical and environmen-
tal isolates and to allow elucidating the source and mode
of transmission of this important bacterium at this medi-
cal center.
Results
Our data have shown that several mechanical devices were
associated with P. aeruginosa infection in our patients with
55% due to mechanical ventilation and the remaining
45% due to polysite catheters, Foley catheters and differ-
ent types of surgery.
RAPD analysis have shown 31 genotypes present among
the clinical and the environmental isolates (figure 1).
Thirty eight of ninety (42%) of the clinical isolates and
10/23 (43%) of the environmental isolates showed geno-
type 1 to be distributed among the medical center units.
Each of the genotypes 2–30 represented from 1–8% of the
strains. Antimicrobial susceptibility testing has shown
that susceptibility patterns between clinical and environ-
mental isolates were similar with most drugs showing >
90% susceptibility, with the exception of tobramycin and
gentamycin which showed lower susceptibility (83%) in
the environmental strains. Data is in concordance with
previous reports in this institution [13]. Enzymatic assays
determined that genotype 1 in addition to other 10 geno-
types, in clinical and environmental isolates, were positive
for all virulence factors tested for. All other genotypes were
all positive for the production of protease, lecithinase and
coagulase and positive in 83–89% of the cases for the pro-
duction of the other 4 virulence factors (Figure 2). Table 1
shows the relationship between the various genotypes, to
source, antibiograms and virulence factors.
Discussion
The strain distribution based on RAPD analysis showed
that clinical and environmental isolates distributed in one
or more than one unit, included genotypes 1–8 and 9,
with predominance of genotype 1 in all investigated units.
This may indicate that cross contamination among
patients lead to the spread of this genotype among the var-
ious units, possibly through transient hand carriage by
health care personnel due to contact with contaminated
surfaces or by patient contact with contaminated surfaces
or medical equipment [4]. Our findings suggest that cross
colonization may be an important means of P. aeruginosa
spread and infection especially after identification of a
potentially virulent clone (genotype 1) of this organism
that had been propagated in various units over a period of
9 months. This could indicate that the patients were con-
tinuously infected with a strain originating from an exog-
enous source. The importance of cross colonization of P.
aeruginosa  in nosocomial infections was previously
reported, by Bergmans et al who studied 100 patients
admitted to an ICU ward; cross colonization accounted
for 50% of all cases of acquired P. aeruginosa colonization,
the other 50% of patients were probably colonized from
endogenous sources [14].
The remaining genotypes were isolated exclusively from
the clinical specimens of patients and were not detected
among environmental isolates. Most of these genotypes
did not harbor all the virulence factors tested for. Not
being encountered in environmental sources may indicate
that these strains may have been endogenously acquired.
High rate of colonization with P. aeruginosa from endog-
enous sources occurs mainly in the respiratory and gas-
trointestinal tracts [2]. Hospitalization may lead to
increased rates of carriage, particularly in the lower respi-
ratory tract in patients undergoing mechanical ventila-
tion, upper respiratory tract due to broncho- pulmonary
colonization and infection, in the gastrointestinal tract of
patients receiving chemotherapy for neoplastic diseases,
or at virtually any site in patients treated with antibiotics
[3,15,16].
Prevalence of strains with resistance to all antimicrobial
agents will constitute a major risk for hospitalized
patients. In our study, though, the most prevalent strain of
genotype 1 was susceptible to all antimicrobial agents and
does not constitute a problem in treatment. However, its
potential of producing all virulence factors and being
spread by various means in the hospital, unlike other gen-
otypes that harbor all virulence factors, may render geno-
type 1 a high risk pathogen specially in the
immunosuppressed and debilitated patients. The fact that
genotype 1 remained susceptible to all antibiotics lead to
the conclusion that patients could be continuously
infected with a strain originating from an exogenous
source.
In addition to mechanical spread by personnel, this geno-
type may carry a number of adhesins that enhance its col-
onization in the hospital environment and render it more
accessible to patients. Studies are underway in our labora-
tory to detect by PCR, genes encoding a number of adhes-
ins and determine their transcription levels in genotype 1,
in comparison to other encountered genotypes. This will
shed light on the possible role of adhesins on the preva-
lence of this genotype in the hospital environment. The
extracellular enzymes or toxins produced, on the other
hand, will contribute to the breaking down physical bar-
riers and help the organism to penetrate, impair hostBMC Microbiology 2005, 5:29 http://www.biomedcentral.com/1471-2180/5/29
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(A) Genotypes of P. aeruginosa isolates found in 10 units Figure 1
(A) Genotypes of P. aeruginosa isolates found in 10 units. Lane 1: 50-bp ladder, lane 2: negative control, lane 3:ATCC25321 
strain, lanes 4–18: Genotypes 1,2,3,4,5,6,7,8,9,10,11,12,13,14, and 15. (B) Lane 16: 50-bp ladder, lane 17: negative control, lane 
18: ATCC 25321 strain, lanes 19–33: Genotypes 16,17,18,19,20,21,22,23,24,25,26,27,28,29, and 30. (C) Genotypes of P. aerugi-
nosa from environmental sources found in the RCU. Lane 1: 50-bp ladder, lane 2: negative control, lane 3:ATCC 25321 strain, 
lane 4–11: Genotypes (1,4,17,25,27,28,30,31).
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defenses, and render its new milieu more conducive to its
physical, nutritional and reproductive requirements [17].
In summary, our data have shown the predominant prev-
alence of a potentially virulent P. aeruginosa genotype 1 in
clinical and environmental specimens, circulating in the
various hospital units. From a practical point of view, the
results of our study emphasize the need to reinforce
implementation of infection control measures, and to
limit the transmission of P. aeruginosa among patients and
from environmental sources to patients. Screening for P.
aeruginosa carriage in all patients with nosocomial coloni-
zation or infection should also be done in research set-
tings using both rectal and respiratory tract specimens to
determine the source of colonization/infection and hence
get informed on whether it was acquired endogenously or
exogenously.
Conclusion
In conclusion, our data have shown the predominant
prevalence of a potentially virulent P. aeruginosa genotype
1 in clinical and environmental specimens, circulating in
the various medical center units.
Methods
Consecutive  P. aeruginosa (90) isolates were recovered
from different patients specimens (one per patient) sub-
mitted for bacteriological investigations at the Clinical
Microbiology Laboratory at the American University of
Beirut Medical Center (AUBMC), between September
2003 and May 2004. Patients acquiring a nosocomial
infection due to P. aeruginosa as determined by clinical
and laboratory testing and indicated in their medical
records, were only considered in this study. Fever, and
recovery of P. aeruginosa from the site of infection during
stay at the medical center, constituted the most important
criteria that defined patient's infection with this organism.
Patients' data collected from the medical records,
included age (2 to 91 years), sex (Males: 43 and Females:
47), admission date, admission diagnosis, invasive proce-
dures used on the patients, symptoms, and the date of the
first positive culture for P. aeruginosa. The drugs used in
the treatment of these patients, mainly included:
Percentage of clinical and environmental P. aeruginosa isolates producing the virulence factors Figure 2
Percentage of clinical and environmental P. aeruginosa isolates producing the virulence factors.
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Table 1: Correlation between P. aeruginosa genotypes, source and site of infection, antimicrobial susceptibility and enzymatic activities 
of virulence factors
Genotypes types of 
unit
Number of 
clinical 
isolates
Isolation 
site/ 
Number of 
isolates
Antibiograms Virulence factors
AN ATM CAZ CIP GM IPM TZ NN Pro Lec Elas Lip Fib Coag
1 RCU 15 DTA1/ 13 
blood/ 1 
Wound/ 1
SS S SSSSS+++ + ++
ICU 3 DTA/ 2 
Wound/ 1
SS S SSSSS+++ + ++
CCU 1 Urine/ 1 S S S S S S S S + + + + + +
PICU 4 DTA/2 
Tongue/ 1 
Wound/ 1
SS S SSSSS+++ + ++
St Jude 1 Wound/ 1 S S S S S S S S + + + + + +
S u r g e r y 3 W o u n d /  3SS S SSSSS+++ + ++
5 South 6 Abscess/ 1 
Sputum/ 2 
DTA/ 1 
Bronchial 
washing/ 1 
Urine/ 1
SS S SSSSS+++ + ++
4 South 2 Sputum/ 1 
Swab/ 1
SS S SSSSS+++ + ++
9 South 3 DTA/ 1 
Sputum/ 1 
Blood/ 1
SS S SSSSS+++ + ++
2 RCU 1 DTA/ 1 S S S S S S S S + + + + + +
ICU 1 DTA/ 1 S S S S S S S S + + + + + +
S u r g e r y 2 W o u n d /  2SS S SSSSS+++ + ++
Oncology 1 Blood/ 1 S S S S S S S S + + + + + +
5 south 1 Pleural fuild/ 
1
SS S SSSSS+++ + ++
3 RCU 2 DTA/ 1 
Wound/ 1
SS S SSSSS+++ + ++
5 South 2 Sputum/ 2 S S S S S S S S + + + + + +
Oncology 3 DTA/ 2 
Blood/ 1
SS S SSSSS+++ + ++
4 RCU 1 DTA/ 1 S S S S S S S S + + + + + +
St Jude 2 Blood/ 1 
Catheter/ 1
SS S SSSSS+++ + ++
5 South 1 Bile/ 1 S S S S S S S S + + + + + +
5 PICU 1 DTA/ 1 S S S S S S S S + + - + + +
4 South 1 DTA/ 1 S S S S S S S S + + - + + +
6 RCU 1 DTA/ 1 S S S S S S S S + + + - + +
ICU 1 Sinus/ 1 S S S S S S S S + + + - + +
7 ICU 2 DTA/ 2 S S S S S S S S + + + - + +
Oncology 1 Blood/ 1 S S S S S S S S + + + - + +
8 ICU 1 DTA/ 1 S S S S S S S S + + + + - +
Oncology 1 Blood/ 1 S S S S S S S S + + + + - +
9 R C U 1 U r i n e /  1 SS S SSSSS+++ + ++
S u r g e r y 1 W o u n d /  1SS S SSSSS+++ + ++
10 4 South 2 Wound/ 2 S S S RRRRR++-+- +
11 Oncology 2 leg ulcer/ 1 
Bronchial 
washing/ 1
SS S SSSSS+++ + ++
12 5 South 2 DTA/ 2 S S S S S S S S + + + - - +
13 9 South 1 Sinus 
discharge/ 1
SS SRRSSR ++-+- +
14 9 South 1 Wound/ 1 S S S S S S S S + + + + + +
15 ICU 1 DTA/ 1 S S S S S S S S + + + - + +BMC Microbiology 2005, 5:29 http://www.biomedcentral.com/1471-2180/5/29
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amikacin, azactam, gentamicin, tobramycin, and tazocin.
Patients were distributed within ten different units in the
medical center, mainly the Respiratory Care Unit (RCU),
Intensive Care Unit (ICU), Coronary Care Unit (CCU),
the Surgery Unit, as well as other units. Twenty three iso-
lates were also collected from different environmental
sources, such as, respirators, respirators' filters, water irri-
gation, tap water, basins, trays, bed side tables, side rails,
and sink sides. Statistical analysis determined the sample
size required to estimate the true proportion (percentage
of P. aeruginosa infections during a given period of time)
to within 0.10, with 95% confidence was calculated. Cal-
culations estimated the minimum number of samples
required to be 54 [9].
The presumptive identification of P. aeruginosa on culture
based on colonial morphology, Gram stain microscopy,
and oxidase test was further confirmed by the API NE Kits
and growth at 42°C. Susceptibility of all isolates to a
panel of antimicrobial agents (amikacin, aztreonam,
ceftazidime, ciprofloxacin, gentamicin, imipenem, piper-
acillin/tazobactam, tobramycin) was determined accord-
ing to the guidelines of the National Committee for
Clinical Laboratory Standards (NCCLS) [10]. P. aeruginosa
ATCC 25321 strain was used as positive control in all
tests.
DNA was extracted from P. aeruginosa ATCC strain and
from all isolates of P. aeruginosa by the GFX™ Genomic
Blood DNA Purification Kit (Amersham PharmaciaBio-
tech, Uppsala, Sweden) according to the manufacturers'
specifications. Random amplified polymorphic DNA
(RAPD) analysis of the clinical and environmental iso-
lates using two in-house oligonucleotide primers, Pa1
(5'AGGGGTCTTG 3') and Pa2 (5' CTTCTTCAGCTC-
GACGCGACG 3') was done. RAPD was carried out
according to Matar et al [11] using the PTC-100™ Pro-
grammable Thermal Controller (MJ Research, Inc., Water-
town, Mass., USA). Briefly, RAPD was carried out on all
isolates in 100 µl reaction mixtures containing each: 10 µl
of template DNA, 16 µl of dNTPs (0.2 mM), 10 µl of 10X
PCR buffer (100 mM TrisHCl [pH 8.3], 500 mM KCl, 4
mM MgCl2), 1 µl of primer 1 (0.5 µM), 1 µl of primer 2
(0.3 µg/ µl), 2.5 U of Taq DNA polymerase and 61.5 µl of
nanopure sterile water. The amplification program,
included the following steps: denaturation at 94°C for 3s,
16 CCU 1 Sternal 
tissue / 1
SS S SSSSS+++ + +-
17 CCU 1 Urine/ 1 S S S S S S S S + + + - + +
18 CCU 1 DTA/ 1 S I S SSSSS++-- -+
19 RCU 1 DTA/ 1 S I S SSSSS+++ + ++
20 RCU 1 DTA/ 1 S S S S S R SS++-+ - +
21 RCU 1 DTA/ 1 S S S S R SSR ++-+- +
22 RCU 1 DTA/ 1 S I S SSSSS+++ + ++
23 RCU 1 DTA/ 1 S I S SSS R S++-+ -+
24 RCU 1 Wound/ 1 R S R RRRRR++-+- +
25 RCU 1 DTA/ 1 S S S S R SSI ++++ ++
26 RCU 1 Sputum/ 1 S RRSSRRS++-+ -+
27 PICU 1 DTA/ 1 S RRSSS R S+++ + ++
28 ICU 1 DTA/ 1 S RRSSIRS+++ + ++
29 4 South 1 DTA/ 1 S I SS RRSS++++ + -
30 RCU 1 DTA/ 1 S S S S R SSI ++-+- +
NB: Genotype 31 was only found among the environmental isolates
1 DTA: Deep Tracheal Aspirate
AN: Amikacin
CIP: Ciprofloxacin
TZ: Tazocin
ATM: Aztreonam
GM: Gentamicin
NN: Tobramycin
CAZ : Ceftazidime
IPM: Imipenem
Pro: Protease
Lip: Lipase
Lec: Lecithinase
Fib: Fibrinolysin
Elas: Elastase
Coag: Coagulase
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annealing at 53°C for 1 min and extension at 72°C for 1
min, for 44 cycles. The cycles were followed by a final
extension step at 72°C for 10 min. Amplicons were sub-
jected to electrophoresis on 2% agarose gels at 107 volts
for 2 hours. Patterns that had the same number of bands
and similar fragments size were considered identical.
The enzymatic activities of the isolates of P. aeruginosa
were evaluated by spot inoculation containing 106 CFU/
ml of the organisms in various media [12]. Media used:
Brain heart infusion for the protease activity, 1% elastin
(Sigma Chemical Co. St Louis, Mo. USA) for the elastase
activity, human fibrinogen type 1 (Sigma Chemical Co. St
Louis, Mo. USA) for the fibrinolytic activity, trypticase soy
agar (TSA) supplemented with egg yolk (Difco Laborato-
ries, Detroit, Mi., USA) for the lecithinase production, TSA
with tween 80 (Sigma Chemical Co. St Louis, Mo. USA)
for the lipase activity, DNase test agar with toluidine blue
0, (Difco Laboratories, Detroit Mi., USA) for the DNAase
production, and rabbit plasma (Difco Laboratories,
Detroit Mi., USA) for the coagulase activity. Positivity of
tests was assessed as follows: clearing of opacity around
the inoculum spots for the protease, elastase and fibrino-
lytic activities, white precipitate around or beneath the
inoculum spots for the lecithinase activity, a turbid halo
around the inoculum spots for the lipase activity, forma-
tion of a pink halo around the inoculum spots for the
DNase activity, and gelling of rabbit plasma after 48 hours
for the coagulase activity.
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